These data support the findings described in "Cross-resistance between Platinum-based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer" by Slootbeek et al. All data traceable to patients (eg. Study ID, date of birth) is excluded from the dataset.

The dataset contains response data of 28 metastatic castration-resistant prostate cancer patients who recieved both a platinum-based chemotherapy and a PARP inhibitor. For conclusions and interpretations, please see the paper.